GUERBET : 3rd quarter 2016 revenue
October 24 2016 - 11:45AM
Revenue at
September 30, 2016
Sales variance stabilized at -2.3%
at constant exchange rates
Level of sales in line with
expectations
Villepinte,
October 24, 2016 - Guerbet (FR0000032526
GBT), a global specialist in contrast agents and solutions for
medical imaging, is reporting revenue of €568.4 million at
September 30, 2016, up 65.4% from 2015, continuing the momentum
started in the first half of 2016. This growth figure includes a
negative currency impact of €13.4 million mainly from the Brazilian
real and the Argentine peso. At constant exchange rates, the Group
posted sales of €581.9 million, a limited decrease of 2.3% from the
pro forma sales at the end of September 2015 and still in line with
the sales stabilization target of +/-3%. With revenue of €191.7
million for third quarter 2016, the strong sales momentum remains
comparable with second quarter 2016 (€193.0 million).
Consolidated Group revenue
(IFRS)
In millions of euros |
9 months 2016 |
9 months 2015
pro forma* |
Change |
Reported 2015 |
1st half 2016 |
1st half 2015
pro forma |
Change |
Sales in
Europe |
274.3 |
282.7 |
-2.9% |
236.7 |
189.7 |
187.5 |
+1.2% |
Sales in
Other Markets |
294.1 |
313.1 |
-6.1% |
106.9 |
187.0 |
210.3 |
-11.1% |
Total |
568.4 |
595.8 |
-4.6% |
343.6 |
376.7 |
397.8 |
-5.3% |
* Integration of
CMDS activities
At constant
exchange rates, sales growth is in line with the revenue
stabilization objective (+/-3%)
In Europe, consolidated revenue at
September 30, 2016 totaled €274.3 million compared with €282.7
million in 2015 in its pro forma version, including a negative
currency impact of €2.8 million. The decline in sales was mainly
confined to Russia. The region's third-quarter revenue totaled
€84.6 million compared with €95.1 million in 2015 (pro forma).
Outside Europe, the Group's sales
fell to €294.1 million compared with €313.1 million in 2015 (pro
forma), including a negative currency effect of €10.6 million. At
constant exchange rates, there was a slight decrease of 2.7%,
benefiting particularly from sales of Dotarem® in the
US. Third-quarter revenue in Other Markets increased to €107.1
million compared with €102.8 million in 2015 (pro forma).
Favorable
momentum in MRI and IRT, growth expected in X-ray and ISS
At constant exchange rates, the
activity breaks down as follows:
-
revenue for MRI totaled
€183.2 million, up 3.7% (€176.6 million pro forma 2015),
-
the X-Ray segment was down
5.9% at €282.5 million, still mainly due to Optiray®,
-
the IRT segment grew 22.3%,
exceeding €40 million in revenue, thanks to the performance of
Lipiodol® and
Patent Blue V,
-
lastly, the Imaging Solutions
and Services (ISS) segment was down 5.9%
with revenue of €58.1 million.
2016 outlook:
confirmation of annual targets
The performance level for the
first nine months of the year is within the window of +/-3%
announced as the full-year target, allowing the Group to confirm
this goal.
Upcoming
events:
2016 revenue:
February 15, 2017, after trading
Guerbet is a pioneer in the
contrast agent field, with 90 years' experience, and is the only
pharmaceutical group dedicated to medical imaging worldwide. It
offers a comprehensive range of X-Ray, Magnetic Resonance Imaging
(MRI) and Interventional Radiology and Theranostics (IRT) products,
along with a range of injectors and related medical devices to
improve the diagnosis and treatment of patients. To discover new
products and ensure future growth, Guerbet invests heavily in
R&D, spending around 9% of its sales each year. Guerbet (GBT)
is listed on Euronext Paris (Segment B - Mid Caps) and generated
€789 million in pro forma revenue in 2015.
For more information about Guerbet,
please visit www.guerbet.com
Jean-François Le Martret
Chief Financial Officer
(+33)(0)1 45 91 50 00
|
Financial Communications
Benjamin Lehari
(+33)(0)1 56 88 11 25
blehari@actifin.fr
Press
Jennifer Jullia
(+33)(0)1 56 88 11 19
jjullia@actifin.fr
|
GUERBET : 3rd quarter 2016
revenue
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: GUERBET via Globenewswire
Guerbet (EU:GBT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Guerbet (EU:GBT)
Historical Stock Chart
From Jul 2023 to Jul 2024